Roxastat API

Name	Roxastat
Chinese name	罗沙司他
Cas Number	808118-40-3
Source	India
Qualifications	USDMF/-/-/-/-

Roxarestat is a domestically developed by Fabojin China and AstraZeneca China. It is a potent and reversible hypoxia inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that can be taken orally. Stabilizes and activates HIF transcription factors and initiates an adaptive transcription response, so that under normal oxygen conditions, it simulates the production of erythrocytes that occurs in the human body under hypoxic environment, including the production of endogenous erythropoietin and Iron mobilization by reducing hepcidin will eventually induce red blood cell production and improve anemia. Before the approval of rosastat, the treatment of renal anemia mainly included iron supplementation, erythropoiesis stimulant (ESAs) treatment (ie injection of erythropoietin EPO) and blood transfusion. The above three traditional therapies are effective and safe. There are limitations in terms of both sex and convenience. In December 2018, Roxastat was the first to be approved for marketing in China for the treatment of anemia in patients with chronic kidney disease on dialysis. In August 2019, the indication for the treatment of anemia in patients with non-dialysis-dependent chronic kidney disease was approved by the NMPA. Roxastat is a useful supplement and improvement to the current treatment of renal anemia, and has a good clinical prospect.

Hot Tags: roxastat api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Pazopanib Hydrochloride Pazopanib API, Salmeterol Xinafoate API, Vinpocetine API, Dapoxetine API, Brinzolamide API, Escitalopram Oxalate API

• Previous: Articaine API
• Next: Oxybutynin Hydrochloride API